Antiviral Resistance Mutations Potentiate Hepatitis B Virus Immune Evasion Through Disruption of Its Surface Antigen a Determinant
Overview
Microbiology
Affiliations
Background: The hepatitis B virus (HBV) pol gene overlaps the S gene encoding surface antigen (HBsAg). It has been reported previously that drug-induced changes in HBsAg alter its binding to sera from humans immunized against HBV. We investigate here the changes to specific epitopes in the a determinant (the major target of neutralizing antibody) caused by a number of drug-resistant mutations.
Methods: Recombinant HBsAgs, produced by transfection of Chinese hamster ovary cells with S gene plasmids into which lamivudine, adefovir and entecavir resistance and common antibody-escape mutations had been introduced, were probed with monoclonal antibodies to epitopes in the first and second loops of the a determinant.
Results: The mutations rtF166L/sF158Y (lamivudine-associated, compensatory) and rtl169T/sF161L (entecavir-associated, primary) acting alone, and the mutations rtV173L/sE164D (lamivudine-associated, compensatory) and rtSilent/sD144E (antibody escape-associated) each when combined with rtM204V/sl195M (lamivudine-associated, primary) led to decreases in antibody reactivity to epitopes in the first or second loop, or in both loops. The rtM204V/sl195M + rtV173L/sE164D mutations yielded an epitope-antibody profile similar to the rtR153Q/sG145R vaccine escape mutant. The rtM204V/sl195M mutation combined with the rtF166L/sF158Y or rtR153Q/sG145R mutation restored reactivity to second-loop epitopes previously abrogated by single mutations.
Conclusions: Mutations associated with resistance to nucleos(t)ide analogue therapy, singly or in combination with each other or antibody escape-associated mutations, alter HBsAg immunoreactivity through concomitant amino acid substitutions at codons within and downstream of the a determinant. The findings have implications for understanding the native structure of HBsAg, optimizing treatment of chronic hepatitis B and evaluating the success of immunization programmes.
Dagnew M, Moges F, Tiruneh M, Million Y, Gelaw A, Adefris M PLoS One. 2022; 17(11):e0276687.
PMID: 36378635 PMC: 9665361. DOI: 10.1371/journal.pone.0276687.
Host Biology and Anthropogenic Factors Affect Hepadnavirus Infection in a Neotropical Bat.
Hiller T, Rasche A, Brandel S, Konig A, Jeworowski L, OMara M Ecohealth. 2018; 16(1):82-94.
PMID: 30564998 PMC: 7088011. DOI: 10.1007/s10393-018-1387-5.
Recent and occult hepatitis B virus infections among blood donors in the United States.
Ramachandran S, Groves J, Xia G, Saa P, Notari E, Drobeniuc J Transfusion. 2018; 59(2):601-611.
PMID: 30499591 PMC: 8190636. DOI: 10.1111/trf.15057.
Hepatitis B Virus Adaptation to the CD8+ T Cell Response: Consequences for Host and Pathogen.
Lumley S, McNaughton A, Klenerman P, Lythgoe K, Matthews P Front Immunol. 2018; 9:1561.
PMID: 30061882 PMC: 6054973. DOI: 10.3389/fimmu.2018.01561.
Overview of hepatitis B viral replication and genetic variability.
Tong S, Revill P J Hepatol. 2016; 64(1 Suppl):S4-S16.
PMID: 27084035 PMC: 4834849. DOI: 10.1016/j.jhep.2016.01.027.